Please check your internet connection and try again.
# Tabevolol
## Overview
Tabevolol is a beta-adrenergic receptor antagonist (beta-blocker).
## Primary Indications
* Hypertension
* Angina pectoris
* Arrhythmias (e.g., supraventricular tachycardia, atrial fibrillation, atrial flutter)
* Post-myocardial infarction
* Heart failure (certain formulations)
## Adult Dosing
* **Hypertension:** Starting dose typically 50-100 mg once or twice daily. Usual maintenance dose 100-200 mg twice daily. Maximum dose typically 400 mg twice daily, but may vary.
* **Angina Pectoris:** Starting dose typically 100 mg twice daily. Usual maintenance dose 200 mg twice daily. Maximum dose typically 400 mg twice daily, but may vary.
* **Arrhythmias:** Specific dosing varies by arrhythmia. For atrial fibrillation/flutter rate control, starting dose typically 50-100 mg twice daily. Maximum dose typically 400 mg twice daily.
* **Post-Myocardial Infarction:** Typically initiated after hemodynamic stability is achieved, often starting at 50 mg three times daily for 2-3 days, then increased to 100 mg twice daily.
* **Heart Failure:** For specific extended-release formulations approved for heart failure, dosing is initiated at a low dose and titrated slowly upwards over several weeks. Example: starting 12.5 mg once daily, titrating to 25 mg once daily, then 50 mg once daily, then 100 mg once daily. Maximum dose depends on formulation (e.g., 200 mg once daily).
## Pediatric Dosing
Dosing in pediatric patients is not well-established and should be based on specialist recommendation and careful monitoring.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; dose reduction may be necessary due to potential accumulation.
* **Renal Impairment:** No specific dose adjustment is routinely recommended for mild to moderate renal impairment. Use with caution in severe renal impairment; monitor for adverse effects.
## Contraindications
* Sinus bradycardia
* Second- or third-degree atrioventricular (AV) block (unless a functioning pacemaker is present)
* Cardiogenic shock
* Decompensated heart failure requiring IV inotropic agents
* Asthma or severe bronchospastic disease
* Raynaud's phenomenon
* Severe peripheral arterial circulatory disorders
* Hypersensitivity to tabevolol or any component of the formulation
## Adverse Effects
Common: Bradycardia, hypotension, fatigue, dizziness, cold extremities, bronchospasm (especially in susceptible individuals), gastrointestinal upset (nausea, diarrhea), depression. Less common: Impotence, masking of hypoglycemia symptoms (except sweating).
## Key Drug Interactions
* **Calcium Channel Blockers (e.g., verapamil, diltiazem):** Increased risk of bradycardia, AV block, and heart failure.
* **Antiarrhythmics (e.g., amiodarone):** Additive effects on cardiac depression and AV conduction.
* **Insulin/Oral Hypoglycemics:** May mask symptoms of hypoglycemia (tachycardia) and potentially prolong hypoglycemia.
* **NSAIDs:** May decrease antihypertensive effect.
* **CYP2D6 Inhibitors (e.g., fluoxetine, paroxetine):** May increase tabevolol plasma concentrations.
* **Rifampin:** May decrease tabevolol plasma concentrations.
## Monitoring
* Heart rate and blood pressure
* Signs and symptoms of heart failure (e.g., dyspnea, edema)
* Signs of peripheral circulation impairment
* Blood glucose levels in diabetic patients
* Pulmonary function in patients with respiratory disease
* Renal and hepatic function
## Clinical Pearls
* Abrupt discontinuation can lead to rebound hypertension, angina, or arrhythmias. Taper dose gradually over 1-2 weeks.
* Use with caution in patients with diabetes due to potential masking of hypoglycemia symptoms.
* Non-selective beta-blockers like tabevolol can exacerbate bronchospasm. Consider cardioselective agents if a beta-blocker is necessary in patients with reactive airway disease.
* When used for heart failure, initiation and titration should occur under close medical supervision.
---
*This information is intended for healthcare professionals and does not replace the need to consult the official prescribing information for Tabevolol or other current medical literature.*
